CXCR4 and neoplasm: Thus, our goal is to tackle the urgent need to develop therapeutic agents that could be exploited to achieve targeted delivery of bacterial exotoxins to CXCR4+ tumor cells and thus reach personalized therapy that enhances the antineoplastic effect while reducing adverse effects in EC patients [14].